title: Alternative prophylactic treatments to lithium in bipolar disorders.
abstract: The research literature on alternative drug treatments to lithium therapy for the prevention of recurrences in bipolar disorders is discussed. In particular, the data on anticonvulsants (carbamazepine and valproic acid), antidepressants (alprazolam), and calcium channel blockers (verapamil) are reviewed and original data on clonazepam (CLN) are reported. In a preliminary study on six patients with bipolar disorders (DSM-III-R) without a history of psychotic features in which lithium prophylaxis was ineffective, contraindicated, or badly tolerated, CLN was administered in combination with low-dose neuroleptics or antidepressants in all but one case. All subjects were followed for 13 to 34 months. There were no relapses during the observation period with CLN dose regimens ranging from 1.5-8 mg/day p.o. Side effects were minimal and mostly consisted of transient sedation.
authors.affiliation: Department of Clinical Psychiatry, University of Milan, Italy.
authors.forename: M C
authors.initials: MC
authors.lastname: Mauri
authors.forename: M
authors.initials: M
authors.lastname: Percudani
authors.forename: M G
authors.initials: MG
authors.lastname: Regazzetti
authors.forename: A C
authors.initials: AC
authors.lastname: Altamura
mesh_terms: D000525:Alprazolam / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy / Q000517:prevention & control*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002220:Carbamazepine / Q000627:therapeutic use; D002998:Clonazepam / Q000627:therapeutic use; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use
chemical_list: D002121:Calcium Channel Blockers; D002220:Carbamazepine; D002998:Clonazepam; D014635:Valproic Acid; D008094:Lithium; D000525:Alprazolam